Sökning: "targeted therapy"
Visar resultat 16 - 20 av 323 avhandlingar innehållade orden targeted therapy.
16. CNS-Targeted Cell Therapy for Multiple Sclerosis
Sammanfattning : Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system (CNS). In the current thesis, we have preformed an immunological investigation of patients with MS and developed an immunosuppressive cell therapy that could be beneficial for these patients. LÄS MER
17. The participation of older people with and without dementia in public space, through the lens of everyday technology use
Sammanfattning : Participation in activities and places within public space has been linked to numerous health benefits and yet, little is known about participation among older people with and without dementia. Insights about participation in activities and places within public space can contribute to the somewhat ambiguous definition of participation, as “involvement in a life situation”, by acknowledging the complexity and interrelatedness of subjective, social, contextual, temporal, and technological aspects of participation. LÄS MER
18. Targeted monoclonal antibody therapy in chronic lymphocytic leukemia
Sammanfattning : Chronic lymphocytic leukemia (CLL) is still regarded as an incurable disease with a great need for developing new therapies and optimizing existing treatment options. The development of targeted therapy, i.e. therapy interfering with specific molecules needed for carcinogenesis and tumor growth, is rapidly evolving. LÄS MER
19. The Multiple Faces of Genetically-Modified T Cells : Potential Applications in Therapy
Sammanfattning : In this PhD thesis the potential of T-cells as therapy for disease are explored. The applications of genetically modified T-cells for treatment of cancer and autoimmune disease; the functionality and optimal activation of T-cells are discussed. LÄS MER
20. Targeted therapy and outcome in chronic lymphocytic leukemia
Sammanfattning : Despite major advances, chronic lymphocytic leukemia (CLL) is still considered incurable. Fludarabine refractory patients and those with TP53disruptions have a particularly poor prognosis. Alemtuzumab is an established treatment option for these patients. However, its use is complicated by immunosuppressive side effects. LÄS MER